Skip to main content
    C

    Co-Diagnostics, Inc. Common Stock (CODX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.22
    -0.03 (-13.03%)

    Market Cap: $2.72M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Co-Diagnostics, Inc. Common Stock (CODX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    Co-Diagnostics, Inc. Common Stock reported revenue of $622.49K for the fiscal year ended Dec 31, 2025, down 84.1% from the year before. That year, net income was -$46.90M with a net margin of -7533.6%, operating cash flow was -$29.14M and free cash flow was -$29.84M. The quarter ended Sep 30, 2026 had revenue of $282.88K and net income of -$6.31M.

    Revenue and Margins

    Over the 8 years to Dec 2025, revenue grew from $7.66K, a compound annual rate of 73.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$622.49K-84.1%64.3%-8058.8%-7533.6%
    Dec 2024$3.92M-42.5%74.5%-1023.7%-961.4%
    Dec 2023$6.81M-80.1%38.6%-626.9%-518.7%
    Dec 2022$34.22M-65.0%84.0%-78.8%-41.6%
    Dec 2021$97.89M+31.3%88.2%47.1%37.5%
    Dec 2020$74.55M+34579.9%77.7%55.9%57.0%
    Dec 2019$214.97K+438.6%47.7%-2741.6%-2882.0%
    Dec 2018$39.91K+420.9%76.5%-15328.6%-15714.3%
    Dec 2017$7.66KN/A96.1%-59567.6%-90827.9%
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$622.49K$3.92M$6.81M$34.22M$97.89M$74.55M$214.97K$39.91K$7.66K$0
    Cost of revenue$222.38K$999.12K$4.18M$5.48M$11.57M$16.59M$112.43K$9.39K$302$0
    Gross profit$400.11K$2.92M$2.63M$28.74M$86.31M$57.96M$102.54K$30.52K$7.36K$0
    Research and development$19.14M$20.98M$22.96M$17.44M$14.96M$3.19M$1.37M$1.36M$1.00M$731.47K
    Operating income-$50.17M-$40.08M-$42.71M-$26.98M$46.06M$41.69M-$5.89M-$6.12M-$4.56M-$1.69M
    Net income-$46.90M-$37.64M-$35.33M-$14.24M$36.66M$42.48M-$6.20M-$6.27M-$6.96M-$1.93M
    EBITDA-$48.46M-$37.11M-$38.14M-$17.94M$46.36M$41.83M-$5.83M-$6.07M-$4.52M-$1.65M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$282.88K$166.13K$145.95K$263.92K$145.38K$162.91K$50.28K$149.32K$641.14K$2.66M$467.85K$3.56M
    Gross profit-$20.46K$120.83K-$47.81K$121.53K$119.09K$130.80K$28.69K-$105.74K$343.74K$2.44M$233.35K$587.34K
    Operating income-$6.27M-$6.20M-$9.21M-$26.54M-$7.01M-$8.06M-$8.55M-$11.91M-$10.23M-$7.68M-$10.26M-$11.83M
    Net income-$6.31M-$6.28M-$9.14M-$25.75M-$5.89M-$7.73M-$7.53M-$11.03M-$9.70M-$7.60M-$9.31M-$14.68M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $662.26K by $11.22M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$24.74M$63.56M$95.32M$123.09M$160.03M$71.24M$2.22M$1.55M$4.66M$1.30M
    Current assets$13.69M$32.29M$62.14M$92.73M$115.12M$67.81M$1.58M$1.05M$4.45M$1.21M
    Cash and equivalents$11.88M$2.94M$14.92M$22.97M$88.61M$42.98M$893.14K$950.24K$3.53M$998.74K
    Total liabilities$4.11M$9.69M$9.31M$8.57M$25.56M$4.54M$478.07K$2.61M$811.80K$4.29M
    Short-term debt$662.26K$915.62K$838.39K$297.21K$6.07MN/AN/A$1.91M$0$2.95M
    Long-term debtN/AN/AN/AN/AN/AN/AN/AN/A$0$445.00K
    Shareholder equity$20.63M$53.88M$86.01M$114.52M$134.48M$66.70M$1.74M-$1.06M$3.85M-$2.99M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$12.79M$16.59M$21.50M$24.74M$44.74M$46.47M$55.15M$64.00M$72.38M$80.70M$86.67M$95.32M
    Total liabilities$3.37M$3.88M$5.46M$4.11M$4.91M$5.33M$7.23M$9.69M$8.60M$8.30M$8.32M$9.31M
    Cash and equivalents$714.80K$3.65M$8.23M$11.88M$11.44M$11.12M$1.90M$2.94M$10.80M$13.86M$23.10M$14.92M
    Shareholder equity$9.43M$12.71M$16.04M$20.63M$39.83M$41.14M$47.92M$54.31M$63.78M$72.40M$78.35M$86.01M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$29.14M-$29.16M-$22.08M$6.57M$41.08M$28.17M-$5.53M-$4.08M-$3.21M-$1.31M
    Capital expenditures$700.05K$748.35K$1.37M$1.43M$669.46K$774.40K$113.25K$41.34K$129.31K$12.24K
    Free cash flow-$29.84M-$29.90M-$23.45M$5.14M$40.41M$27.39M-$5.64M-$4.12M-$3.34M-$1.32M
    Share repurchasesN/AN/A$1.36M$14.21M$0$1.46M$592.76KN/A$0N/A
    Investing cash flow$26.27M$17.07M$15.39M-$58.17M$4.10M-$5.82M-$435.25K-$380.34K-$189.31K-$12.24K
    Financing cash flow$11.81M$103.91K-$1.36M-$14.03M$450.40K$19.74M$5.90M$1.88M$5.94M$2.29M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$5.68M-$7.15M-$7.85M-$6.20M-$5.90M-$8.29M-$8.75M-$8.23M-$7.23M-$5.20M-$8.49M-$4.78M
    Capital expenditures$15.00K$18.28K$142.02K$131.97K$75.11K$401.06K$91.91K$72.99K$174.44K$98.63K$402.29K$464.60K
    Free cash flow-$5.70M-$7.17M-$7.99M-$6.33M-$5.98M-$8.69M-$8.84M-$8.30M-$7.40M-$5.30M-$8.89M-$5.24M
    Last 12 quarters

    Frequently Asked Questions About CODX

    What is Co-Diagnostics, Inc. Common Stock's annual revenue?

    Co-Diagnostics, Inc. Common Stock reported revenue of $622.49K for the fiscal year ended Dec 31, 2025.

    How fast is Co-Diagnostics, Inc. Common Stock's revenue growing?

    Revenue was down 84.1% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -73.7%.

    Is Co-Diagnostics, Inc. Common Stock profitable?

    No. Co-Diagnostics, Inc. Common Stock reported net income of -$46.90M for the fiscal year ended Dec 31, 2025, with a net margin of -7533.6%.

    How much free cash flow does CODX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$29.14M minus capital expenditures of $700.05K produced free cash flow of -$29.84M.

    How much debt does Co-Diagnostics, Inc. Common Stock have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $662.26K and cash and equivalents of $11.88M.